Payment overview · 2025
General Payments
$662.66
23 reported records · 15 companies
Healthcare provider profile · identity verified
Kyle Matthew Smith, DO
Allopathic & Osteopathic Physicians|Family Medicine · BAY SHORE, NY · NPI 1093212441
Verified facts
What the public records show
CMS Open Payments records show Kyle Matthew Smith, DO received $662.66 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 502 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $217.32 | 32.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $120.52 | 18.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.59 | 7.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.88 | 6.9% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $34.34 | 5.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.76 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.68 | 3.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.42 | 3.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.83 | 3.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.39 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.74 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.14 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.87 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.16 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.02 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $662.66 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $186.21 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $180.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.17 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
502 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 193 |
| Eliquis | Apixaban | 502 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 124 |
| Alprazolam | Alprazolam | 395 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 115 |
| Sertraline Hcl | Sertraline Hcl | 301 | 57 |
| Furosemide | Furosemide | 293 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 65 |
| Gabapentin | Gabapentin | 274 | 82 |
| Losartan Potassium | Losartan Potassium | 251 | 100 |
| Oxycodone Hcl | Oxycodone Hcl | 226 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 60 |
| Potassium Chloride | Potassium Chloride | 210 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 96 |
| Mirtazapine | Mirtazapine | 166 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 31 |
| Metformin Hcl | Metformin Hcl | 158 | 59 |
| Trazodone Hcl | Trazodone Hcl | 143 | 62 |
| Prednisone | Prednisone | 139 | 74 |
| Simvastatin | Simvastatin | 133 | 54 |
| Tramadol Hcl | Tramadol Hcl | 130 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 68 |
| Memantine Hcl | Memantine Hcl | 120 | 20 |
| Donepezil Hcl | Donepezil Hcl | 119 | 26 |
| Baclofen | Baclofen | 118 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 52 |
| Famotidine | Famotidine | 115 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 64 |
| Azithromycin | Azithromycin | 104 | 95 |
| Omeprazole | Omeprazole | 104 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 27 |
| Lisinopril | Lisinopril | 101 | 42 |
| Montelukast Sodium | Montelukast Sodium | 97 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 46 |
| Spironolactone | Spironolactone | 84 | 25 |
| Pregabalin | Pregabalin | 82 | 17 |
| Carvedilol | Carvedilol | 80 | 28 |
| Cephalexin | Cephalexin | 76 | 63 |
| Clonazepam | Clonazepam | 75 | 22 |
| Xarelto | Rivaroxaban | 72 | 16 |
| Meloxicam | Meloxicam | 71 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 17 |
| Divalproex Sodium | Divalproex Sodium | 68 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 68 | 31 |
| Lorazepam | Lorazepam | 66 | 17 |
| Warfarin Sodium | Warfarin Sodium | 65 | suppressed |
| Latanoprost | Latanoprost | 63 | 22 |
| Diazepam | Diazepam | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 53 |
| Januvia | Sitagliptin Phosphate | 60 | 11 |
| Atenolol | Atenolol | 59 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Risperidone | Risperidone | 54 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 23 |
| Albuterol Sulfate | Albuterol Sulfate | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 24 |
| Methenamine Hippurate | Methenamine Hippurate | 52 | 13 |
| Ozempic | Semaglutide | 52 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 38 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Glimepiride | Glimepiride | 46 | 16 |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 34 |
| Nystatin | Nystatin | 45 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 16 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 20 |
| Olanzapine | Olanzapine | 43 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 18 |
| Azelastine Hcl | Azelastine Hcl | 42 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Loperamide | Loperamide Hcl | 38 | 17 |
| Valsartan | Valsartan | 38 | 14 |
| Metformin Hcl Er | Metformin Hcl | 37 | 21 |
| Alendronate Sodium | Alendronate Sodium | 36 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Methylprednisolone | Methylprednisolone | 33 | 26 |
| Sucralfate | Sucralfate | 32 | 16 |
| Bupropion Xl | Bupropion Hcl | 31 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Finasteride | Finasteride | 30 | 17 |
| Levetiracetam | Levetiracetam | 30 | 13 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 30 | 16 |
| Fentanyl | Fentanyl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Torsemide | Torsemide | 28 | 12 |
| Admelog Solostar | Insulin Lispro | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | 11 |
| Meclizine Hcl | Meclizine Hcl | 24 | 18 |
| Methimazole | Methimazole | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | 15 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | 14 |
| Santyl | Collagenase Clostridium Hist. | 24 | 12 |
| Ssd | Silver Sulfadiazine | 24 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | 17 |
| Midodrine Hcl | Midodrine Hcl | 23 | 11 |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | 12 |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 13 |
| Nyamyc | Nystatin | 20 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 17 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 11 |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | 13 |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | 11 |
| Generlac | Lactulose | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 14 | 12 |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Brilinta | Ticagrelor | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Naproxen | Naproxen | 11 | 11 |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $662.66 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DUPIXENT, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Veozah, XYOSTED, ZAVZPRET, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error